Homepage | Lupus Science & Medicine
Lupus Science & Medicine® is a global, peer reviewed, open access online journal that provides a central point for publication of basic, clinical, translational, and epidemiological studies of all aspects of lupus and related diseases. An official journal of the Lupus Foundation of America (LFA), which is dedicated to advancing the science and medicine of lupus while offering support to ...
Clinical trial outcomes for SLE: what we have and what we need
The paradigm of drug approval in SLE currently relies on successful large phase III randomised controlled trials and a set of primary, secondary and additional end points. Taken together, these outcomes offer a nuanced understanding of the efficacy and safety of the investigational agent. In this review, we thoroughly examine the main outcomes used in SLE trials and highlight unmet ...
Lufi, et≥al Lupus Science Medicine 20229e000718 doi101136/lupus-2022-000718 1 Utility of the ACR- 1997, SLICC-2012 and EULAR/ACR-2019classificationcriteria forsystemiclupuserythematosus:a single-centreretrospectivestudy
Homepage | Lupus Science & Medicine
A lupus journal publishing basic, clinical, translational and epidemiological studies on all aspects of lupus and related diseases. An official journal of Lupus Foundation of America.
20 Diagnosis and treatment of neuropsychiatric lupus
Aug 31, 2020 · Neuropsychiatric (NP) involvement is one of the most complex and challenging features of systemic lupus erythematosus (SLE) encompassing the central (CNS), peripheral (PNS) and autonomous nervous system (ANS) as defined by the 1999 American College of Rheumatology standard nomenclature and case definitions. NPSLE has a negative impact on patient’s quality of life and is associated with ...
Thanoua etΔal Lupus Science Medicine 216e365 doi11136lupus21365 1 Scoring systemic lupus erythematosus (SLE) disease activity with simple, rapid outcome measures Aikaterini Thanou , 1 Judith A James,1,2 Cristina Arriens , 1 Teresa Aberle,1 Eliza Chakravarty,1 Joseph Rawdon,1 Stavros Stavrakis,2 Joan T Merrill,1 Anca Askanase3 To cite: Thanou A, James JA, ...
van VollenhovenflRF, etfial Lupus Science Medicine 20218e000538 doi101136lupus-2021-000538 1 2021 DORIS definition of remission in SLE: final recommendations from an international task force Ronald F van Vollenhoven ,1 George Bertsias,2 Andrea Doria ,3 David Isenberg,4 Eric Morand ,5 Michelle A Petri ,6 Bernardo A Pons-Estel ,7 Anisur Rahman,8 Manuel Francisco Ugarte-Gil ,9,10
01 When and how to escalate therapy in an impending flare
Sep 4, 2019 · Twenty to thirty percent of patients with systemic lupus erythematosus (SLE) patients experience a disease flare each year. Official definitions are available: The most used are based on physician decisions to change treatment; if treatment is added or escalated, that defines flare. Much research has focused on detecting flares before symptoms occur. The most effective and available is a ...
YuanS, et≥al Lupus Science Medicine 20229e000660 doi101136/lupus2022000660 Lupus Science & Medicine: first published as 10.1136/lupus-2022-000660 on 22 June 2022. Downloaded from https://lupus.bmj.com on 21 January 2025 by guest. All rights, including for text and data1 Phenotypical changes and clinical
MahranfiSA etfial Lupus Science Medicine 2218e521 doi11136lupus221521 1 Peripheral neuropathy in systemic lupus erythematosus: what can neuromuscular ultrasonography (NMUS) tell us? A cross-sectional study